WO2006073443A3 - Anticorps monoclonaux anti-cd40 antagonistes et leurs methodes d'utilisation - Google Patents

Anticorps monoclonaux anti-cd40 antagonistes et leurs methodes d'utilisation Download PDF

Info

Publication number
WO2006073443A3
WO2006073443A3 PCT/US2005/014359 US2005014359W WO2006073443A3 WO 2006073443 A3 WO2006073443 A3 WO 2006073443A3 US 2005014359 W US2005014359 W US 2005014359W WO 2006073443 A3 WO2006073443 A3 WO 2006073443A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
binding
c4bp
mediated
methods
Prior art date
Application number
PCT/US2005/014359
Other languages
English (en)
Other versions
WO2006073443A2 (fr
Inventor
Mohammad Luqman
Original Assignee
Chiron Corp
Mohammad Luqman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Mohammad Luqman filed Critical Chiron Corp
Priority to US11/587,911 priority Critical patent/US20070292439A1/en
Priority to JP2007510907A priority patent/JP2008509080A/ja
Priority to CA002564296A priority patent/CA2564296A1/fr
Priority to AU2005323515A priority patent/AU2005323515A1/en
Priority to EP05856653A priority patent/EP1761311A2/fr
Priority to BRPI0510317-7A priority patent/BRPI0510317A/pt
Priority to MXPA06012430A priority patent/MXPA06012430A/es
Publication of WO2006073443A2 publication Critical patent/WO2006073443A2/fr
Publication of WO2006073443A3 publication Critical patent/WO2006073443A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)

Abstract

L'invention concerne des compositions et des méthodes d'inhibition d'activités dirigées vers CD40 à médiation de liaison de C4BP à CD40. Lesdites compositions renferment des anticorps anti-CD40 ou des fragments associés de liaison à l'antigène qui présentent les caractéristiques suivantes: (1) ils sont exempts d'une activité agoniste CD40 importante lorsqu'ils sont liés à l'antigène CD40 et (2) ils sont capables de se lier spécifiquement à l'antigène CD40 exprimé à la surface des cellules, la liaison à l'antigène CD40 bloquant la signalisation CD40 à médiation C4BP, ce qui permet d'inhiber au moins une activité dirigée vers CD40. Ces anticorps anti-CD40 antagonistes peuvent être utilisés efficacement pour traiter des maladies associées à CD40 qui sont médiées par une stimulation C4BP de la signalisation CD40, notamment, des cancers tels que des cancers liés au lymphocyte B et des tumeurs solides et des maladies ou des troubles qui ont un composé auto-immun et/ou inflammatoire, y compris, un rejet de greffe de tissu ou d'organe.
PCT/US2005/014359 2004-04-27 2005-04-27 Anticorps monoclonaux anti-cd40 antagonistes et leurs methodes d'utilisation WO2006073443A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US11/587,911 US20070292439A1 (en) 2004-04-27 2005-04-27 Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
JP2007510907A JP2008509080A (ja) 2004-04-27 2005-04-27 アンタゴニスト抗ｃｄ４０モノクローナル抗体およびその使用方法
CA002564296A CA2564296A1 (fr) 2004-04-27 2005-04-27 Anticorps monoclonaux anti-cd40 antagonistes et leurs methodes d'utilisation
AU2005323515A AU2005323515A1 (en) 2004-04-27 2005-04-27 Antagonist anti-CD40 monoclonal antibodies and methods for their use
EP05856653A EP1761311A2 (fr) 2004-04-27 2005-04-27 Anticorps monoclonaux anti-cd40 antagonistes et leurs methodes d'utilisation
BRPI0510317-7A BRPI0510317A (pt) 2004-04-27 2005-04-27 anticorpos monoclonais anti-cd40 antagonistas e métodos para seu uso
MXPA06012430A MXPA06012430A (es) 2004-04-27 2005-04-27 Anticuerpos monoclonales antagonistas anti-cd40 y metodos para su uso.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56577504P 2004-04-27 2004-04-27
US60/565,775 2004-04-27

Publications (2)

Publication Number Publication Date
WO2006073443A2 WO2006073443A2 (fr) 2006-07-13
WO2006073443A3 true WO2006073443A3 (fr) 2006-10-12

Family

ID=36579251

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014359 WO2006073443A2 (fr) 2004-04-27 2005-04-27 Anticorps monoclonaux anti-cd40 antagonistes et leurs methodes d'utilisation

Country Status (10)

Country Link
EP (1) EP1761311A2 (fr)
JP (1) JP2008509080A (fr)
KR (1) KR20070026522A (fr)
CN (1) CN101014386A (fr)
AU (1) AU2005323515A1 (fr)
BR (1) BRPI0510317A (fr)
CA (1) CA2564296A1 (fr)
MX (1) MXPA06012430A (fr)
RU (1) RU2006141632A (fr)
WO (1) WO2006073443A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008207898B2 (en) * 2007-01-23 2012-05-03 Xencor, Inc Optimized CD40 antibodies and methods of using the same
WO2009062054A1 (fr) * 2007-11-09 2009-05-14 Novartis Ag Utilisation d'anticorps anti-cd40
AU2009206506B2 (en) 2008-01-23 2013-01-10 Xencor, Inc. Optimized CD40 antibodies and methods of using the same
RS57114B1 (sr) 2010-03-31 2018-06-29 Boehringer Ingelheim Int Anti-cd40 antitela
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (fr) 2010-11-30 2012-06-07 Novartis Ag Utilisation d'anticorps anti-cd40 en thérapie combinée contre des cancers associés aux cellules b
MY165090A (en) 2011-04-21 2018-02-28 Bristol Myers Squibb Co Antibody polypeptides that antagonize cd40
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR20150106872A (ko) * 2012-11-05 2015-09-22 가부시키가이샤 레그이뮨 면역 관용 유도제
US10435475B2 (en) 2014-03-07 2019-10-08 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize CD40 to treat IBD
CN106573981A (zh) 2014-08-12 2017-04-19 鳄鱼生物科学公司 利用抗cd40抗体的组合疗法
EP3344655B1 (fr) * 2015-09-01 2023-07-26 Boehringer Ingelheim International GmbH Utilisation d'anticorps anti-cd40 pour le traitement de la néphrite lupique
WO2017059196A2 (fr) 2015-09-30 2017-04-06 Janssen Biotech, Inc. Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation
EA039944B1 (ru) * 2016-01-27 2022-03-30 Бёрингер Ингельхайм Интернациональ Гмбх Применение антител к cd40 для лечения волчаночного нефрита
RU2756236C2 (ru) 2016-06-20 2021-09-28 Кимаб Лимитед PD-L1 специфические антитела
US11525005B2 (en) 2017-06-01 2022-12-13 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
WO2019198019A1 (fr) * 2018-04-13 2019-10-17 Novartis Ag Anticorps anti-cd40 destinés à être utilisés dans la prévention du rejet de greffe
AR117091A1 (es) * 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
US20220025060A1 (en) 2018-11-30 2022-01-27 Jiangsu Hengrui Medicine Co., Ltd. Anti-cd40 antibody, antigen binding fragmentand pharmaceutical use thereof
KR20210097750A (ko) 2018-11-30 2021-08-09 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Cd40 항체 약학 조성물 및 이의 용도
KR102356829B1 (ko) * 2019-01-30 2022-01-28 주식회사 에프엔씨티바이오텍 폐 섬유화 질환 진단 또는 치료를 위한, m-csf 또는 g-csf의 이용
CN111763259B (zh) * 2020-09-03 2020-12-15 北京百奥赛图基因生物技术有限公司 抗cd40抗体及其用途
JP2024506831A (ja) 2021-01-28 2024-02-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイトカイン放出症候群を治療するための組成物及び方法
WO2024054992A1 (fr) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Procédés de séparation d'agent chélateur

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0945465A1 (fr) * 1992-07-09 1999-09-29 Chiron Corporation Anticorps monoclonaux antagonistes contre la molécule humaine CD40
WO2001024823A1 (fr) * 1999-10-04 2001-04-12 Chiron Corporation Antagonistes de cd40 permettant de traiter le psoriasis
WO2001083755A2 (fr) * 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Anticorps humains anti-cd40, et leurs procedes de production et d'utilisation
EP1391464A1 (fr) * 2001-04-27 2004-02-25 Kirin Beer Kabushiki Kaisha Anticorps monoclonal anti-cd40

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0945465A1 (fr) * 1992-07-09 1999-09-29 Chiron Corporation Anticorps monoclonaux antagonistes contre la molécule humaine CD40
WO2001024823A1 (fr) * 1999-10-04 2001-04-12 Chiron Corporation Antagonistes de cd40 permettant de traiter le psoriasis
WO2001083755A2 (fr) * 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Anticorps humains anti-cd40, et leurs procedes de production et d'utilisation
EP1391464A1 (fr) * 2001-04-27 2004-02-25 Kirin Beer Kabushiki Kaisha Anticorps monoclonal anti-cd40

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANGELINI F ET AL: "C4B-BINDING PROTEIN (C4BP) BINDS CD40 AND MODULATES CD40 SIGNALING", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 107, no. 2, 16 March 2001 (2001-03-16), pages S137, XP009030662, ISSN: 0091-6749 *
BOON L ET AL: "Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys", TOXICOLOGY, LIMERICK, IR, vol. 174, 2002, pages 53 - 65, XP002954468, ISSN: 0300-483X *
BRODEUR S R ET AL: "C4b-binding protein (C4BP) activates B cells through the CD40 receptor", IMMUNITY, CELL PRESS, US, vol. 18, no. 6, June 2003 (2003-06-01), pages 837 - 848, XP002279363, ISSN: 1074-7613 *
CLARK E A ET AL: "A CD40 bridge between innate and adaptive immunity", IMMUNITY, CELL PRESS, US, vol. 18, no. 6, June 2003 (2003-06-01), pages 724 - 725, XP002279364, ISSN: 1074-7613 *
ELLMARK P ET AL: "Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library", IMMUNOLOGY, BLACKWELL PUBLISHING, OXFORD, GB, vol. 106, no. 4, August 2002 (2002-08-01), pages 456 - 463, XP002326342, ISSN: 0019-2805 *
MALMBORG A-C M ET AL: "Affinity and epitope profiling of mouse anti-CD40 monoclonal antibodies", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, BLACKWELL SCIENCE PUBL., OXFORD, GB, vol. 57, no. 6, June 2003 (2003-06-01), pages 517 - 524, XP002326343, ISSN: 0300-9475 *

Also Published As

Publication number Publication date
RU2006141632A (ru) 2008-06-10
WO2006073443A2 (fr) 2006-07-13
AU2005323515A1 (en) 2006-07-13
EP1761311A2 (fr) 2007-03-14
CA2564296A1 (fr) 2006-07-13
CN101014386A (zh) 2007-08-08
JP2008509080A (ja) 2008-03-27
BRPI0510317A (pt) 2007-10-16
KR20070026522A (ko) 2007-03-08
MXPA06012430A (es) 2007-04-19

Similar Documents

Publication Publication Date Title
WO2006073443A3 (fr) Anticorps monoclonaux anti-cd40 antagonistes et leurs methodes d'utilisation
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
ZA200806610B (en) Anti-IL-6 antibodies preventing the binding of IL-6 complexed with IL-6ralpha to GP130
WO2006070286A3 (fr) Anticorps monoclonaux contre le nkg2a
EP1603949B8 (fr) Anticorps diriges contre le recepteur humain de l'il-21 et utilisations correspondantes
WO2011004028A3 (fr) Agents de liaison à tlr3
WO2007042573A3 (fr) Compositions et procedes pour traiter des troubles de proliferation
WO2006071960A3 (fr) Compositions et procedes de traitement de troubles de la proliferation cellulaire
ZA200701656B (en) Humanized anti-cment antagonists
IL169152A0 (en) Antibodies against pd-1 and uses therefor
WO2006096487A3 (fr) Methodes et compositions de modulation de l'activite de tweak et de fn14
WO2006004910A3 (fr) Anticorps bispecifiques ameliores
TW200745163A (en) Peptides that block the binding of IgG to FcRn
WO2004039774A3 (fr) Inhibiteurs de kinesine mitotique
WO2003099211A3 (fr) Inhibiteurs de kinesine mitotique
WO2005017190A3 (fr) Inhibiteurs de kinesine mitotique
WO2006068933A3 (fr) Inhibiteurs de la kinesine mitotique
WO2006023852A3 (fr) Modulateurs des recepteurs muscariniques
WO2007100640A3 (fr) Traitement du cancer a l'aide d'antagonistes du recepteur de l'hormone de croissance
WO2006078574A3 (fr) Inhibiteurs mitotiques de la kinesine
WO2006031348A3 (fr) Inhibiteurs de la kinesine mitotique
WO2005110491A3 (fr) Methodes de traitement du cancer
WO2005065183A3 (fr) Inhibiteurs mitotiques de la kinesine
WO2006078598A3 (fr) Inhibiteurs de la kinesine mitotique
WO2011116212A3 (fr) Agents de liaison de récepteur de protéine morphogénétique osseuse et procédés de leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005323515

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2564296

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007510907

Country of ref document: JP

Ref document number: PA/a/2006/012430

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 3166/KOLNP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005323515

Country of ref document: AU

Date of ref document: 20050427

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005323515

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020067024587

Country of ref document: KR

Ref document number: 2005856653

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006141632

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200580020729.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020067024587

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005856653

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11587911

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0510317

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 11587911

Country of ref document: US